Skip Navigation

Japanese Journal of Clinical Oncology 2005 35(3):121-125; doi:10.1093/jjco/hyi036
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Osanai, T.
Right arrow Articles by Sugihara, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osanai, T.
Right arrow Articles by Sugihara, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2005 Foundation for Promotion of Cancer Research

Inverse Correlation Between the Expression of O6-Methylguanine-DNA Methyl Transferase (MGMT) and p53 in Breast Cancer

Takayuki Osanai, Yoko Takagi, Yoichi Toriya, Tsuyoshi Nakagawa, Tomoyuki Aruga, Satoru Iida, Hiroyuki Uetake and Kenichi Sugihara

Surgical Oncology, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan

For reprints and all correspondence: Takayuki Osanai, 1-5-45, Yushima, Bunkyo-ku, Tokyo, Japan. E-mail: t-osanai.srg2{at}tmd.ac.jp

Received August 28, 2004; accepted January 2, 2005

Background: Expression of O6-methylguanine-DNA methyl transferase (MGMT), a DNA repair protein, has been associated with tumor resistance to alkylating agents such as cyclophosphamide. Promoter hypermethylation of MGMT is a strong predictor of survival, and expression of mutant p53 protein may be associated with downregulated MGMT expression in brain tumors. In order to clarify further the correlation between MGMT and p53 expression, we investigated the expression levels of both MGMT and p53 in breast cancer.

Methods: MGMT and p53 expression was examined in tissues from 48 consecutive cases of primary breast cancer patients using immunohistochemical staining with antibodies specific for MGMT and p53. The prognosis for survival was analyzed based on MGMT and p53 immunoreactivity and clinicopathological characteristics.

Results: Expression of either MGMT or p53 was classified as negative or positive based on immunohistochemical staining. The expression of MGMT showed a significant inverse correlation with three clinicopathological characteristics, the status of the estrogen receptor, local recurrence and distant metastasis. There was a significant correlation between the expression level of p53 and the lymphatic involvement, estrogen receptor status and distant metastasis. MGMT and p53 were correlated with distant metastasis and local recurrence, but Kaplan–Meier curves did not show a significant difference. MGMT immuno-negative specimens showed a significantly higher expression of p53 (P = 0.026, {chi}2 test).

Conclusion: p53 may be associated with the regulation of MGMT expression in breast cancers.

Key Words: O6-methylguanine • DNA methyl transferase (MGMT) • breast cancer • p53


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. D. Konduri, J. Ticku, G. C. Bobustuc, R. M. Sutphin, J. Colon, B. Isley, K. K. Bhakat, S. S. Kalkunte, and C. H. Baker
Blockade of MGMT Expression by O6 Benzyl Guanine Leads to Inhibition of Pancreatic Cancer Growth and Induction of Apoptosis
Clin. Cancer Res., October 1, 2009; 15(19): 6087 - 6095.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Sakakura, K. Hasegawa, K. Miyagawa, S. Nakashima, T. Yoshikawa, S. Kin, Y. Nakase, S. Yazumi, H. Yamagishi, T. Okanoue, et al.
Possible Involvement of RUNX3 Silencing in the Peritoneal Metastases of Gastric Cancers
Clin. Cancer Res., September 15, 2005; 11(18): 6479 - 6488.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.